Syncona sets its sights on a gene therapy turnaround
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
ESGCT 2022 – Sangamo strengthens its case in Fabry
The group looks like the gene therapy contender to beat, but that is not saying much.
Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea
The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
4D gets a good start in Fabry
But a serious adverse event and waning enzyme levels raise questions about the data.
Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Idorsia’s Fabry flop puts focus on gene therapies
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
